NO20032441L - Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer - Google Patents

Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Info

Publication number
NO20032441L
NO20032441L NO20032441A NO20032441A NO20032441L NO 20032441 L NO20032441 L NO 20032441L NO 20032441 A NO20032441 A NO 20032441A NO 20032441 A NO20032441 A NO 20032441A NO 20032441 L NO20032441 L NO 20032441L
Authority
NO
Norway
Prior art keywords
diabetic
combination
prodrug
dehydrogenase inhibitors
sorbitol dehydrogenase
Prior art date
Application number
NO20032441A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032441D0 (no
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20032441D0 publication Critical patent/NO20032441D0/no
Publication of NO20032441L publication Critical patent/NO20032441L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20032441A 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer NO20032441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
NO20032441D0 NO20032441D0 (no) 2003-05-28
NO20032441L true NO20032441L (no) 2003-07-03

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032441A NO20032441L (no) 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Country Status (38)

Country Link
US (1) US6544998B2 (de)
EP (1) EP1337271B1 (de)
JP (1) JP2004514699A (de)
KR (1) KR20030059290A (de)
CN (1) CN1477975A (de)
AP (1) AP2001002360A0 (de)
AR (1) AR031431A1 (de)
AT (1) ATE281181T1 (de)
AU (1) AU2002215159A1 (de)
BG (1) BG107774A (de)
BR (1) BR0115783A (de)
CA (1) CA2430298A1 (de)
CR (1) CR6964A (de)
CZ (1) CZ20031399A3 (de)
DE (1) DE60106968T2 (de)
DO (1) DOP2001000289A (de)
EA (1) EA200300432A1 (de)
EC (1) ECSP034624A (de)
EE (1) EE200300248A (de)
ES (1) ES2230378T3 (de)
HR (1) HRP20030420A2 (de)
HU (1) HUP0302160A3 (de)
IL (1) IL155704A0 (de)
IS (1) IS6786A (de)
MA (1) MA26964A1 (de)
MX (1) MXPA03004870A (de)
NO (1) NO20032441L (de)
OA (1) OA12534A (de)
PA (1) PA8534101A1 (de)
PE (1) PE20020597A1 (de)
PL (1) PL365927A1 (de)
PT (1) PT1337271E (de)
SK (1) SK6192003A3 (de)
SV (1) SV2003000751A (de)
TN (1) TNSN01169A1 (de)
UY (1) UY27042A1 (de)
WO (1) WO2002043762A2 (de)
ZA (1) ZA200303381B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
PL366384A1 (en) * 2001-05-25 2005-01-24 Warner-Lambert Company Llc Liquid pharmaceutical composition
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
AU2005231433A1 (en) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Controlled release dosage for GABA receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
CN101160287B (zh) 2005-02-17 2011-08-03 安斯泰来制药株式会社 吡啶基非芳香族含氮杂环-1-羧酸酯衍生物
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
US20090170867A1 (en) * 2007-04-27 2009-07-02 Shionogi & Co., Ltd. Trpv1 antagonists including sulfonamide substituent and uses thereof
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと1または2種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
EP3753410A3 (de) * 2010-09-28 2021-04-28 The Regents Of The University Of California Kombinationen enthaltend gaba agonisten zur behandlung von hyperglyzemie
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN113966396A (zh) * 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
JPS5625169A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
MXPA01009871A (es) * 1999-04-01 2002-04-24 Pfizer Prod Inc Aminopiridinas como inhibidores de la sorbitol deshidrogenasa.
EP1041068B1 (de) * 1999-04-01 2004-04-14 Pfizer Products Inc. Verbindungen zur Behandlung und Vorsorge bei Diabetes

Also Published As

Publication number Publication date
ECSP034624A (es) 2003-07-25
CA2430298A1 (en) 2002-06-06
BG107774A (en) 2004-01-30
AP2001002360A0 (en) 2001-12-31
EE200300248A (et) 2003-10-15
SK6192003A3 (en) 2004-07-07
OA12534A (en) 2006-06-05
ES2230378T3 (es) 2005-05-01
PA8534101A1 (es) 2002-10-31
AU2002215159A1 (en) 2002-06-11
US6544998B2 (en) 2003-04-08
DE60106968D1 (de) 2004-12-09
IL155704A0 (en) 2003-11-23
EA200300432A1 (ru) 2003-10-30
HRP20030420A2 (en) 2004-08-31
MA26964A1 (fr) 2004-12-20
JP2004514699A (ja) 2004-05-20
TNSN01169A1 (fr) 2005-11-10
EP1337271A2 (de) 2003-08-27
AR031431A1 (es) 2003-09-24
CZ20031399A3 (cs) 2004-04-14
WO2002043762A2 (en) 2002-06-06
PE20020597A1 (es) 2002-07-08
UY27042A1 (es) 2002-07-31
HUP0302160A3 (en) 2005-05-30
CN1477975A (zh) 2004-02-25
CR6964A (es) 2004-02-02
PL365927A1 (en) 2005-01-10
KR20030059290A (ko) 2003-07-07
NO20032441D0 (no) 2003-05-28
ZA200303381B (en) 2004-04-30
PT1337271E (pt) 2005-01-31
WO2002043762A3 (en) 2003-03-13
DOP2001000289A (es) 2003-02-15
US20020091128A1 (en) 2002-07-11
MXPA03004870A (es) 2003-08-19
BR0115783A (pt) 2003-09-16
ATE281181T1 (de) 2004-11-15
DE60106968T2 (de) 2005-11-03
IS6786A (is) 2003-04-14
SV2003000751A (es) 2003-01-13
EP1337271B1 (de) 2004-11-03
HUP0302160A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
NO20032441L (no) Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer
AP2001002359A0 (en) Combination of gaba agonists and aldose reductase inhibitors.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
SG171649A1 (en) Dpp iv inhibitor formulations
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
NO20070987L (no) Polysulfaterte glykosider og salter av disse.
NO20073854L (no) Doseringsform og fremgangsmate for vedvarende frigjoring av en substituert pyrazinforbindelse
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
BRPI0507052A (pt) inibidores de quìnase
DOP2002000373A (es) Composiciones que contienen imidazotriazinona para administración nasal
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
BR0108087A (pt) Método e composições para o tratamento de uma doença inflamatória
WO2007109363A3 (en) Methods and compositions for inhibiting impdh isoform 1
WO2002032411A3 (en) Combination of statins and sorbitol dehydrogenase inhibitors
WO2006036624A3 (en) Lipid stabilized formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application